BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Total Non-current Assets
All assets not expected to be converted to cash within one year.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 1676.5% from a year ago
Total non-current assets stood at $151.14M at the end of Q1 FY2026, up 1676.5% from a year earlier and up 559.4% from the prior quarter. Over 3 fiscal years it compounded at +441.2% a year.
Context
- Total non-current assets amounted to 36.2% of total assets at the end of Q1 FY2026, up 30.5 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +1676.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 22.92M USD
- Year-over-year change
- -88.1%
- 4-year CAGR
- +255.0%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.92M | -88.1% |
| FY2024 | 2024-12-31 | 192.47M | +57718.5% |
| FY2023 | 2023-12-31 | 332.89K | +130.3% |
| FY2022 | 2022-12-31 | 144.58K | +0.2% |
| FY2021 | 2021-12-31 | 144.28K | — |
Total Non-current Assets vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +1676.5% is the highest of 10, against a peer median of -2.6%.
- Total non-current assets amounts to 36.2% of total assets for BBOT, versus a peer median of 7.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $201.75M USD | -44.9% | +17.3% | 27.8% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $151.14M USD | +1676.5% | +441.2% | 36.2% |
| Sep 2026 | $116.53M USD | -18.1% | -8.9% | 55.6% | |
SEPNSepterna, Inc. | Sep 2026 | $112.06M USD | -2.5% | +252.5% | 18.1% |
| Aug 2026 | $91.61M USD | +11.9% | -6.1% | 7.7% | |
| Sep 2026 | $40.8M USD | -12.0% | -9.8% | 3.9% | |
| Mar 2026 | $28.55M USD | -2.6% | +91.5% | 9.4% | |
| Mar 2026 | CHF 16.91M CHF | +9.9% | +8.4% | 6.9% | |
| Mar 2026 | $16.23M USD | +55.4% | +29.1% | 6.4% | |
| Mar 2026 | $13.58M USD | -77.0% | -55.7% | 4.1% | |
| Peer median (excluding BBOT) | — | -2.6% | +8.4% | 7.7% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.